J-Pop Stars Pump up the World’s Largest Projection Mapping Show at the Tokyo Metropolitan Government Building
14.8.2024 07:44:00 EEST | Business Wire | Press release
A meteoric J-pop duo with a huge global following has pitched in to boost the world’s largest projection mapping show and help illuminate midsummer nights in Tokyo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808176674/en/
YOASOBI / Butai ni Tatte (Standing on the Stage) (Photo: Business Wire)
An artwork, combining YOASOBI’s up-tempo vocal and instrumental music with a riot of images and colors, made its debut on the TOKYO Night & Light program on July 26. The nightly show uses the exterior of the 243-meter-tall Tokyo Metropolitan Government (TMG) No. 1 Building as its screen. Three other projections created by internationally acclaimed artists also joined the menu over the same weekend.
YOASOBI – female vocalist Ikura, 23, and male singer-songwriter Ayase, 30 - has contributed the newly composed “Butai ni Tatte (Standing on the Stage),” which echoes the emotions of athletes ready for competition. The song has been adopted by Japan’s public broadcasting corporation NHK as a theme song for its sports programs, and its first Night & Light presentation was timed to coincide with the Paris Olympics opening ceremony.
For the first screening, a horde of people gathered at the Citizens’ Plaza at the foot of the 48-story building, a landmark in the business and entertainment hub of Shinjuku. They watched animated silhouette images of runners and other athletes romp around on the wall.
The Night & Light project has lived up to the TMG’s goal of creating a “new tourism resource to color Tokyo’s nightlife,” attracting 280,000 visitors in five months since its launch on February 25. Projected onto an area, 127 meters by 110 meters, the show has been certified by Guinness World Records™ as the “largest architectural projection-mapped display (permanent).”
Screened every half an hour between 7:30 p.m. and 9:30 p.m. at present, the program strings together a few projections for 15 minutes. On weekends and holidays, the series feature crowd pullers such as the world-famous Japanese movie monster Godzilla and a work inspired by traditional Japanese Ukiyo-e paintings. “Standing on the Stage,” 3.5 minutes long, is to be screened every night for the time being.
Meaning a “night out,” YOASOBI is a global household name five years after its debut. Its hit “Idol,” the theme tune for the TV animation “Oshi no Ko,” became the first Japanese song to top Billboard’s Global (excluding U.S.) chart in June last year. It was also acknowledged as Japan’s best popular song in terms of royalties in the year to March 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808176674/en/
Contacts
TOKYO Night & Light PR Office
press@tokyonightandlight.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom